ALAN YAGODA, M.D.; BIJAY MUKHERJI, M.D.; CHARLES YOUNG, M.D.; ERLINDA ETCUBANAS, M.D.; CHARLES LAMONTE, M.D.; JULIUS R. SMITH, M.D.; CHARLOTTE T. C. TAN, M.D.; IRWIN H. KRAKOFF, M.D., F.A.C.P.
Bleomycin, a mixture of antibiotic polypeptides, was evaluated for therapeutic activity and clinical toxicology in 274 patients with far-advanced, nonresectable neoplastic disease. Therapeutic effect was most marked in advanced Hodgkin's disease, in which 50% of patients had significant objective and subjective improvement, in some cases for periods now approaching 2 years. Scattered responses of brief duration were seen in other neoplastic diseases. The clinical toxicity of bleomycin appears to be unique among antitumor agents; it produces no important effects on the blood-forming organs, gastrointestinal tract, liver, kidneys, or central nervous system. Pulmonary functional impairment, however, is common; irreversible pulmonary fibrosis, although rare, is a serious, sometimes lethal, manifestation of bleomycin toxicity that may limit its use in early neoplastic disease.
YAGODA A, MUKHERJI B, YOUNG C, et al. Bleomycin, an Antitumor Antibiotic: Clinical Experience in 274 Patients. Ann Intern Med. 1972;77:861–870. doi: 10.7326/0003-4819-77-6-861
Download citation file:
Published: Ann Intern Med. 1972;77(6):861-870.
Emergency Medicine, Hematology/Oncology, Interstitial Lung Disease, Leukemia/Lymphoma, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use